The National Science Foundation (NSF) awarded a $274,438 SBIR Phase I grant to Script Biosciences Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project, titled "CASPLUS: A Safer, More Efficient, and Targeted Method of Deploying CRISPR In Vivo," aims to develop a platform technology that significantly reduces the potential inaccuracy of current gene editing techniques. The innovation targets the desired gene, increasing the safety and efficacy of gene editing, which is critical for advancing promising gene-based therapies for difficult-to-treat conditions like leukemia, multiple myeloma, muscular dystrophy, and cystic fibrosis. The Phase I effort will optimize the gene editing formulation, determine the delivery dose for testing in a mouse model, and assess the feasibility of using the innovation in a mouse model targeting myotonic dystrophy type 1, a disease with no current treatments. This SBIR award reflects NSF's mission to support early-stage research and development of innovative technologies with the potential for significant societal and economic impact.
Generated 1/28/25, 11:04 AM